Stockwatch: Politics And Profits May Pollute Pharma’s Pandemic Response
Vaccine Nationalism And Financial Imperatives Generate Friction
It is hard enough speeding novel vaccines against novel pathogens to global markets whilst balancing profit imperatives with societal benefit. Political interventions have the potential to introduce additional friction.
You may also be interested in...
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
The FDA’s rejection of Acadia’s label expansion into a broader patient population for its only approved drug resulted in an aggrieved reaction. Better disclosure from both sides would have helped.
Conventional wisdom from the first biosimilar launches was that the European market that was far tougher on innovator products than was the US. More recent data suggest that things may play out differently in the long run.